Comparative Pharmacology
Head-to-head clinical analysis: LIVOSTIN versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVOSTIN versus ZYRTEC ALLERGY.
LIVOSTIN vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocabastine is a selective histamine H1-receptor antagonist, inhibiting histamine release from mast cells and basophils.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
1 drop (0.05% ophthalmic solution) in affected eye twice daily, up to 4 times daily if needed.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life in adults: 35-40 hours; clinical context: supports once-daily dosing, with steady-state reached after approximately 7 days
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Renal excretion as unchanged drug and metabolites: ~70% (48% unchanged, 9% as levocabastine glucuronide, 13% as other metabolites); fecal excretion: ~20%
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category C
Category C
Antihistamine
Antihistamine